Talis Biomedical Corp
TLISDelisted Sep 20, 2024- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001584751
Talis Biomedical Corp was delisted on Sep 20, 2024; its insiders filed their last Form 4 on Sep 9, 2024; 18 institutions reported holding it in 13F filings for Q2 2024, worth $6.84M in total; Greenlight Capital was the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in Talis Biomedical Corp as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- 0 vs. Q1 2024
- Shares held
- 789.5K
- −3.03K (−0.4%) vs. Q1 2024
- Total value
- $6.84M
- −$92.5K (−1.3%) vs. Q1 2024
- New holders
- 2
- 2 more added
- Sold out
- 2
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TLIS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $26 |
| Q3 2024 | 2 | $460.4K |
| Q2 2024 | 18 | $6.84M |
| Q1 2024 | 18 | $6.93M |
| Q4 2023 | 18 | $5.93M |
| Q3 2023 | 19 | $4.27M |
| Q2 2023 | 22 | $5.27M |
| Q1 2023 | 22 | $5.76M |
| Q4 2022 | 27 | $5.60M |
| Q3 2022 | 29 | $8.59M |
| Q2 2022 | 35 | $12.1M |
| Q1 2022 | 45 | $23.6M |
| Q4 2021 | 47 | $70.2M |
| Q3 2021 | 38 | $119.2M |
| Q2 2021 | 43 | $184.0M |
| Q1 2021 | 45 | $269.0M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Talis Biomedical Corp; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | 2 | $18 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 3 | $26 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 11 | $95 | 0.00% | −109−90.8% | Reduced |
| Bank of America Corp | 13 | $113 | 0.00% | +13 | New |
| Larson Financial Group LLC | 14 | $121 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 84 | $727 | 0.00% | −38−31.1% | Reduced |
| Morgan Stanley | 87 | $754 | 0.00% | −548−86.3% | Reduced |
| Steward Partners Investment Advisory, LLC | 147 | $1.27K | 0.00% | +147 | New |
| Tower Research Capital LLC (TRC) | 877 | $7.60K | 0.00% | −50−5.4% | Reduced |
| BlackRock Inc. | 4,271 | $37.0K | 0.00% | −440−9.3% | Reduced |
| Susquehanna International Group, LLP | 11,607 | $102.1K | 0.00% | −5,824−33.4% | Reduced |
| Renaissance Technologies LLC | 12,299 | $106.5K | 0.00% | +2,000+19.4% | Added |
| Geode Capital Management, LLC | 14,020 | $123.4K | 0.00% | +2,130+17.9% | Added |
| Prelude Capital Management, LLC | 14,928 | $129.3K | 0.01% | 00.0% | Unchanged |
| Vanguard Group Inc | 31,013 | $268.6K | 0.00% | 00.0% | Unchanged |
| BML Capital Management, LLC | 42,743 | $370.2K | 0.27% | 00.0% | Unchanged |
| DME Capital Management, LPSuperinvestorGreenlight Capital | 149,052 | $1.29M | 0.06% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 508,323 | $4.40M | 0.06% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −13−100.0% | Sold out |